Melanoma By The State: Arizona
Arizona touts itself as being home to three of the sunniest cities in the United States—Yuma, Phoenix, and Tucson—and for…
03/19/2019
Melanoma By The State: Arizona
Arizona touts itself as being home to three of the sunniest cities in the United States—Yuma, Phoenix, and Tucson—and for…
|
03/19/2019
Suzanne Lescure: One Woman, One Eye, One Extraordinary Survivor
By Vallerie A. Malkin Suzanne Lescure has always felt lucky. She has a devoted husband. She was able to stay…
|
01/14/2019
Melanoma By The State: Nevada
The seventh largest state in land area in the United States, Nevada boasts a rugged landscape filled with desert valleys…
|
01/14/2019
Tanya Lafontaine, Melanoma Survivor: “I’ve Got This”
by Vallerie A. Malkin Tanya Lafontaine is a 45-year-old mother, fitness professional, and Stage IV melanoma survivor. She is here to…
|
01/10/2019
AIM Launches Peer to Peer Mentoring Program
AIM at Melanoma is pleased to announce Peer Connect, a peer-to-peer mentoring program for anyone touched by melanoma. Here’s how…
11/13/2018
Melanoma International Collaborative Adaptive Trials: Progress Report
The first adaptive platform trial in melanoma—and one of the only adaptive platform trials that will be in existence for…
|
|
11/13/2018
Melanoma Legislation: Progress Report
The facts are straightforward: Indoor tanning before 18 years of age increases one’s risk of melanoma by 85%,1 and the…
|
11/13/2018
Global Advocacy: Progress Report
Melanoma is a global disease. In the United States, one person dies every 54 minutes from melanoma. Australia and New…
|
11/13/2018
The Melanoma Tissue Bank: Progress Report
As we look back through 2018, perhaps the most exciting news from AIM at Melanoma is the progress on what…
|
|
10/08/2018
Grocery Shopping Tips for Melanoma Caregivers
Shop with a list: Make copies of a standard a grocery list that can be added to each week which includes…
|
Recent Posts
Sep. 15, 2024
Long-term Results Continue to Show a Benefit with Nivolumab and Ipilimumab
Sep. 15, 2024
Ten Years of Pembrolizumab Shows Sustained Results
Sep. 15, 2024
Oncolytic Virotherapy Shows Promise in Advanced Melanoma that Failed Immunotherapy
Sep. 15, 2024
New Therapies Under Investigation for Patients With Metastatic Uveal Melanoma
Sep. 14, 2024